Can-Fite BioPharma (NYSE:CANF) Downgraded by StockNews.com to Sell

Posted by Paula Ricardo on Oct 17th, 2024

StockNews.com cut shares of Can-Fite BioPharma (NYSE:CANF – Free Report) from a hold rating to a sell rating in a research note released on Monday.

Separately, EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th.

Check Out Our Latest Stock Report on Can-Fite BioPharma

Can-Fite BioPharma Trading Down 1.8 %

Shares of NYSE CANF opened at $2.70 on Monday. The stock has a market cap of $9.56 million, a P/E ratio of -1.51 and a beta of 1.41. Can-Fite BioPharma has a twelve month low of $1.81 and a twelve month high of $4.69. The stock has a 50 day moving average of $2.27 and a two-hundred day moving average of $2.49.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its position in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the SEC. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.